TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Similarly, a recent exploratory subgroup analysis for patients enrolled in the ECHELON-2 study demonstrated the role of consolidative ASCT in patients with CD30-positive PTCL who achieved CR following treatment with brentuximab vedotin plus CHP (31).